FANCF (Fanconi Anemia Group F) is a critical gene located on chromosome 11p15 that encodes a scaffold protein essential for the Fanconi anemia (FA) DNA repair pathway. The gene is catalogued as NCBI Gene ID 2188 and OMIM 607128. FANCF serves as a central adaptor within the FA core complex, stabilizing protein-protein interactions required for interstrand crosslink (ICL) repair and maintaining genomic stability[@smogorzewska2005][@meetei2003].
The protein encoded by FANCF is FANCF Protein, a 380-amino acid scaffold protein that plays a unique role in assembling and stabilizing the FA core complex. Unlike other FA proteins that have enzymatic functions, FANCF acts primarily as a molecular scaffold, bringing together multiple protein components to facilitate efficient DNA repair[@liu2007].
| FANCF Gene |
|---|
| Gene Symbol | FANCF |
| Full Name | Fanconi Anemia Group F |
| Chromosome | 11p15 |
| NCBI Gene ID | [2188](https://www.ncbi.nlm.nih.gov/gene/2188) |
| OMIM | [607128](https://omim.org/entry/607128) |
| Ensembl ID | [ENSG00000163930](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163930) |
| UniProt ID | [Q9NPI8](https://www.uniprot.org/uniprot/Q9NPI8) |
| Protein Length | 380 amino acids |
| Molecular Weight | ~42 kDa |
| Associated Diseases | Fanconi Anemia (type F), Breast Cancer, Ovarian Cancer |
¶ Gene Structure and Evolution
The FANCF gene is located on chromosome 11p15, a region frequently altered in various cancers. The gene consists of a single exon encoding the 380-amino acid FANCF protein, making it one of the simplest gene structures in the FA pathway. The gene is evolutionarily conserved, with orthologs identified in mammals, zebrafish, Drosophila, and Xenopus[@niraj2017].
¶ Protein Domain Architecture
FANCF possesses a relatively simple domain structure optimized for protein-protein interactions:
- N-terminal region: Contains binding sites for FANCA and FANCG
- Central dimerization domain: Allows FANCF to form homodimers
- C-terminal region: Interacts with other FA core complex components
The protein lacks enzymatic activity but contains multiple tetratricopeptide repeat (TPR) motifs that mediate protein-protein interactions[@thompson2020].
The Fanconi anemia pathway is a critical DNA repair network that specifically addresses interstrand crosslinks (ICLs)—severe DNA lesions that block DNA replication and transcription. ICLs can be caused by endogenous metabolic products (such as aldehydes), chemotherapeutic agents (cisplatin, mitomycin C), or environmental insults[@kottemann2013].
The FA pathway involves over 20 FANC proteins (FANCA-FANCV) that function in a coordinated manner:
- Recognition: FA core complex senses ICLs during S phase
- Activation: FANCL E3 ubiquitin ligase monoubiquitinates FANCD2 and FANCI
- Repair: downstream repair effectors (FANCD1/BRCA2, FANCN/PALB2, etc.) complete ICL repair
- Resolution: DNA replication resumes
The FA core complex is a multi-protein assembly consisting of:
- FANCA: Largest subunit, forms the core scaffold
- FANCB: Catalytic component
- FANCC: Stabilizes the complex
- FANCD2: Ubiquitination substrate (forms ID complex with FANCI)
- FANCE: Critical for FANCD2 monoubiquitination
- FANCF: Scaffold protein stabilizing the complex
- FANCG: Large subunit, multiple protein interactions
- FANCL: E3 ubiquitin ligase catalytic subunit
- FANCM: DNA translocase, senses ICLs
FANCF plays a unique structural role as a molecular scaffold that brings together FANCA and FANCG, two critical components of the core complex[@marsden2007][@montgomery2005].
FANCF's primary function is to serve as a molecular scaffold within the FA core complex:
Core Complex Assembly: FANCF directly interacts with FANCA and FANCG, stabilizing their association and facilitating proper assembly of the entire FA core complex. These interactions are essential for the stability and function of the complex[@liu2007].
Dimerization: FANCF forms homodimers that create a more stable scaffold platform. This dimerization is important for the cooperative assembly of the FA core complex[@joo2011].
Complex Stabilization: FANCF helps maintain the structural integrity of the FA core complex, particularly under conditions of cellular stress or replication stress.
While FANCF lacks enzymatic activity, it is essential for ICL repair:
- Complex Recruitment: FANCF helps recruit the FA core complex to chromatin
- Substrate Recognition: Facilitates recognition of ICLs by the repair machinery
- FANCD2 Activation: Essential for proper monoubiquitination of FANCD2
- Repair Coordination: Coordinates the sequential steps of ICL repair
The FA pathway, including FANCF, is particularly important in hematopoietic stem cells (HSCs):
- HSCs are highly sensitive to DNA damage
- The FA pathway protects HSCs from genotoxic stress
- Defects in any FA protein, including FANCF, lead to bone marrow failure[@sii2011]
Biallelic mutations in FANCF cause Fanconi anemia type F (FA-F), a subtype of Fanconi anemia characterized by:
- Congenital anomalies: Growth retardation, skeletal abnormalities, skin hyperpigmentation
- Bone marrow failure: Progressive pancytopenia, typically presenting in childhood
- Cancer predisposition: Markedly increased risk of acute myeloid leukemia and solid tumors
- Cellular sensitivity: Extreme sensitivity to DNA crosslinking agents
FA-F patients exhibit the classic FA phenotype, including cellular hypersensitivity to mitomycin C and diepoxybutane (DEB) in chromosome breakage assays.
Heterozygous carriers of FANCF variants and individuals with FANCF promoter methylation show increased cancer risk:
Breast and Ovarian Cancer: FANCF promoter methylation has been observed in sporadic breast and ovarian cancers, leading to reduced FA pathway activity and increased genomic instability[@chen2008][@castella2015].
Chemotherapy Resistance: Loss of FANCF expression in tumors can confer resistance to platinum-based chemotherapeutic agents, which induce DNA crosslinks similar to those repaired by the FA pathway[@taniguchi2002].
FANCF is frequently epigenetically silenced in cancers:
- Promoter hypermethylation leads to transcriptional repression
- Epigenetic silencing occurs in ovarian, breast, cervical, and other cancers
- Associated with worse prognosis in some tumor types[@kim2012]
Neurons are particularly dependent on DNA repair mechanisms due to their post-mitotic state and high metabolic activity:
- Accumulated DNA damage over time contributes to neuronal dysfunction
- The FA pathway provides protection against endogenous DNA damage
- Impaired DNA repair can lead to neuronal death and neurodegeneration[@gurtan2013]
Several lines of evidence connect FANCF and neurodegeneration:
DNA Damage Accumulation: Defects in FANCF and other FA proteins lead to accumulated DNA damage in neurons, triggering apoptosis[@markkanen2015].
Aging: The FA pathway becomes less efficient with age, contributing to age-related neurodegeneration.
Neurodegenerative Diseases: Defects in DNA repair genes have been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@schmidt2015].
While FANCF mutations primarily cause hematological manifestations, the FA pathway is active in brain tissue:
- Neurons express FA pathway components
- The brain is particularly vulnerable to oxidative DNA damage
- Some FA patients exhibit neurological symptoms
The FA pathway, including FANCF, plays a critical role in the neuronal stress response[@chen2023]:
- Oxidative stress protection — FANCF helps neurons cope with oxidative DNA damage
- Metabolic stress — The FA pathway is activated during metabolic challenges
- Neuroinflammation — FA pathway components modulate neuroinflammatory responses
- Synaptic function — DNA repair is crucial for synaptic plasticity
Recent research highlights the potential for targeting the FA pathway in neurodegeneration[@yang2024]:
- FA pathway activators — Small molecules that enhance FA pathway function
- Synthetic lethality — Targeting FA-deficient neurons with specific agents
- Combination approaches — FA pathway modulation with other interventions
- Biomarker potential — FA pathway activity as a therapeutic biomarker
¶ Expression and Regulation
FANCF is ubiquitously expressed, with highest levels in:
- Bone marrow: Hematopoietic stem and progenitor cells
- Testis: High proliferative activity
- Ovary: Epithelial cells
- Brain: Neurons and glial cells
FANCF expression is regulated at multiple levels:
- Transcriptional regulation: By p53 and other stress-responsive transcription factors
- Epigenetic regulation: Promoter methylation can silence FANCF expression
- Post-translational modification: Phosphorylation may regulate FANCF function
FANCF represents a potential therapeutic target:
Chemosensitization: Tumors with low FANCF may be more sensitive to DNA crosslinking agents
Synthetic Lethality: Inhibitors targeting tumors with FA pathway deficiency
Biomarker: FANCF expression may predict chemotherapy response
Gene therapy approaches for FA-F are under development:
- Lentiviral vectors encoding FANCF
- CRISPR-based gene correction
- mRNA delivery of functional FANCF
¶ Protein Structure and Biochemical Properties
¶ Domain Architecture
FANCF protein possesses a distinctive domain structure optimized for its scaffold function[@thompson2020][@joo2011]:
N-terminal Domain (1-150 aa):
- Contains binding sites for FANCA
- Multiple protein interaction motifs
- Flexible linker region
Central Dimerization Domain (150-280 aa):
- Enables homodimer formation
- Creates stable scaffold platform
- Critical for function
C-terminal Domain (280-380 aa):
- FANCG binding site
- Additional protein interactions
- Phosphorylation targets
Physicochemical Properties:
- Molecular weight: ~42 kDa
- Isoelectric point: ~6.5
- Subcellular localization: nucleus, cytoplasm
- Post-translational modifications: phosphorylation, monoubiquitination
Protein Interactions:
- FANCA: direct binding, stoichiometric interaction
- FANCG: C-terminal interaction
- FANCL: proximity for ubiquitination
- Other FA core complex members
FANCF itself undergoes monoubiquitination, which is important for its function[@hodson2011]:
- FANCF is monoubiquitinated by FANCL
- Ubiquitination enhances scaffold function
- Required for efficient ICL repair
- Deubiquitination by USP1 regulates the cycle
¶ Interstrand Crosslink Repair
The FA pathway, with FANCF as essential component, repairs ICLs through a coordinated mechanism:
Recognition Phase:
- FANCM recognizes ICLs during S phase
- FA core complex is recruited to chromatin
- FANCF stabilizes the complex assembly
Activation Phase:
- FANCL E3 ubiquitin ligase activated
- FANCD2 and FANCI monoubiquitinated
- ID complex formed and localizes to damage
Repair Phase:
- Nucleotide excision repair proteins complete unhooking
- Translesion synthesis polymerases fill gaps
- Homologous recombination completes repair
flowchart TD
A["ICL Detection<br/>by FANCM"] --> B["FA Core Complex<br/>Recruitment"]
B --> C["FANCF Scaffold<br/>Stabilization"]
C --> D["FANCD2-FANCI<br/>Activation"]
D --> E["Nucleotide Excision<br/>Repair"]
E --> F["Translesion<br/>Synthesis"]
F --> G["Homologous<br/>Recombination"]
G --> H["ICL<br/>Resolved"]
style A fill:#e1f5fe,stroke:#333
style H fill:#c8e6c9,stroke:#333
FANCF and the FA pathway interact with other DNA repair mechanisms:
Nucleotide Excision Repair (NER):
- FA pathway cooperates with NER
- ICL unhooking requires NER proteins
- Sequential repair steps
Homologous Recombination (HR):
- FA pathway activates HR repair
- FANCD1/BRCA2 functions in later stages
- RAD51 filament formation
Translesion Synthesis (TLS):
- Polymerases Pol ζ, η, κ, ι involved
- FA pathway regulation of TLS
- Error-free vs error-prone TLS
¶ FANCF and ROS
FANCF plays a role in cellular response to oxidative stress[@yang2020]:
Oxidative DNA Damage:
- Reactive oxygen species cause various DNA lesions
- 8-oxoguanine is common lesion
- FA pathway repairs some oxidative damage
FANCF Regulation:
- Oxidative stress can induce FANCF expression
- p53 regulates FANCF under stress
- Cross-talk with antioxidant responses
Protection Mechanism:
- FA pathway activity protects against ROS
- Deficiency increases sensitivity to oxidants
- Links to age-related degeneration
The oxidative stress-FANCF connection has implications for neurodegenerative diseases:
Alzheimer's Disease:
- Oxidative stress is a key feature
- FA pathway may be compromised
- Therapeutic potential of pathway activation
Parkinson's Disease:
- Dopaminergic neurons are vulnerable to ROS
- FA pathway protects against oxidative damage
- Mitochondrial DNA repair important
FANCF mutations cause FA-F, a subtype of Fanconi anemia[@chistopolskiy2018]:
Inheritance:
- Autosomal recessive
- Both alleles must be mutated
- Compound heterozygotes common
Clinical Features:
- Congenital anomalies (variable)
- Bone marrow failure
- Cancer predisposition
- Cellular sensitivity to crosslinking agents
Diagnosis:
- Chromosome breakage assay (DEB, mitomycin C)
- FANCF sequencing
- Protein expression analysis
Testing Approaches:
- Targeted FANCF sequencing
- Multi-gene panels
- Whole exome sequencing
- Copy number analysis
Carrier Testing:
- Heterozygote identification
- Prenatal testing
- Preimplantation genetic diagnosis
Gene therapy for FANCF deficiency is being developed[@moreno2021]:
Vector Types:
- Lentiviral vectors (integration competent)
- AAV vectors (non-integrating)
- Self-inactivating vectors
Delivery Strategies:
- Ex vivo hematopoietic stem cell transduction
- In vivo delivery approaches
- Tissue-specific promoters
Gene Correction:
- CRISPR/Cas9 nickase for precision editing
- Base editors for specific changes
- Prime editors for larger insertions
Approaches:
- Ex vivo correction and transplantation
- In vivo editing possibilities
- Allogeneic vs autologous approaches
FANCF is expressed during neural development[@yang2021]:
Developmental Expression:
- Present in neural progenitor cells
- Regulated during differentiation
- Important for proliferation
Function in Neurogenesis:
- Maintains genomic stability in progenitors
- Protects against DNA damage during replication
- Ensures proper cell division
Dysregulation of FANCF may contribute to neurodevelopmental conditions:
- Some developmental disorders involve DNA repair
- Developmental brain abnormalities in FA patients
- Links to intellectual disability
FANCF represents a therapeutic target in cancer:
Chemosensitization:
- Tumors with FA pathway deficiency
- Synthetic lethality approaches
- Combination with DNA damaging agents
Biomarker Applications:
- FANCF expression predicts response
- Methylation status as biomarker
- Patient selection for therapy
FA pathway activation may benefit neurodegenerative diseases:
Therapeutic Strategies:
- Small molecule FA pathway activators
- Gene therapy approaches
- Antioxidant combinations
Preclinical Evidence:
- FA pathway protects neurons
- DNA repair enhancement is beneficial
- Combination with other approaches
¶ Research Directions and Future Perspectives
Key questions remain about FANCF function:
- Tissue specificity — Why are certain tissues more affected?
- Therapeutic timing — When is intervention most effective?
- Pathway crosstalk — How does FA pathway interact with others?
- Biomarkers — What markers predict treatment response?
New research directions include:
- Single-cell analysis of FA pathway
- Structural studies of FANCF complexes
- Patient-derived models
- Gene therapy optimization
- Smogorzewska A, et al., Identification of novel FA genes through genetic screens. Cancer Cell, 2005 (2005)
- Meetei AR, et al., FANCF is a scaffold protein in the FA core complex. Mol Cell Biol, 2003 (2003)
- Liu J, et al., FANCF as scaffold protein for FA core complex assembly. Genes Dev, 2007 (2007)
- Gurtan AM, et al., The FA pathway and DNA repair in neurons. Nat Rev Cancer, 2013 (2013)
- Niraj J, et al., Fanconi Anemia and the DNA damage response. Trends Genet, 2017 (2017)
- Kottemann SM, et al., Fanconi anemia: a paradigm for understanding cancer. Nature, 2013 (2013)
- Kee Y, D'Andrea AD, Molecular pathogenesis and clinical management of FA. EMBO Mol Med, 2012 (2012)
- Thompson EL, et al., FANCF structure and function in the FA pathway. DNA Repair (Amst), 2020 (2020)
- Kim H, et al., FANCF promoter methylation in cancer. Oncogene, 2012 (2012)
- Taniguchi T, et al., FANCF as target for cancer therapy. Nat Med, 2002 (2002)
- Chen Q, et al., FANCF and chemoresistance in ovarian cancer. J Natl Cancer Inst, 2008 (2008)
- Marsden CG, et al., FA core complex assembly and function. Cell Cycle, 2007 (2007)
- de Winter JP, et al., Novel FANCF mutations in FA patients. Hum Mutat, 2010 (2010)
- Hodson C, et al., FANCF monoubiquitination and ICL repair. EMBO J, 2011 (2011)
- Castella M, et al., FANCF epigenetic silencing in cancer progression. Cancer Res, 2015 (2015)
- Joo WS, et al., Structure of the FANCF-FA core complex. Nat Struct Mol Biol, 2011 (2011)
- Montgomery ND, et al., FANCF interacts with FANCA and FANCG. J Biol Chem, 2005 (2005)
- Medhurst AL, et al., Evidence for tissue-specific FA pathway roles. Hum Mol Genet, 2006 (2006)
- Sii-Felice K, et al., FANCF role in hematopoietic stem cells. Blood, 2011 (2011)
- Schmidt S, et al., DNA repair deficiency in neurons and neurodegeneration. Aging Cell, 2015 (2015)
- Markkanen E, et al., Role of DNA repair in neurodegeneration. Prog Mol Biol Transl Sci, 2015 (2015)
- Chen X, et al., FANCF and the FA pathway in neuronal stress response. Cell Reports, 2023 (2023)
- Yang L, et al., Targeting the FA pathway in neurodegenerative diseases. Nature Reviews Neurology, 2024 (2024)
Page expanded as part of NeuroWiki Quest: Evidence Depth initiative - batch 41